Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLUMBUS-AMD: FYB201 vs Lucentis in neovascular age-related macular degeneration
2015-001961-20Phase 3Completed
- Sponsor
- Bioeq AG
- Start
- Sep 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Bioeq AG. Primary endpoint: Change from baseline in BCVA by ETDRS letters at 2 months. Started Sep 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2015-001961-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001961-20.